Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−1.965SEK
−249.11 MSEK
35.22 MSEK
129.58 M
About ONCOPEPTIDES AB
Sector
CEO
Sofia Heigis
Headquarters
Stockholm
Website
Employees (FY)
57
Founded
2000
ISIN
SE0009414576
FIGI
BBG00NRVWP19
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RN4 is 2.955 SEK — it has decreased by 6.28% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange ONCOPEPTIDES AB NPV stocks are traded under the ticker 0RN4.
ONCOPEPTIDES AB NPV is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
0RN4 stock is 6.73% volatile and has beta coefficient of 0.03. Check out the list of the most volatile stocks — is ONCOPEPTIDES AB NPV there?
0RN4 earnings for the last quarter are −0.44 SEK per share, whereas the estimation was −0.68 SEK resulting in a 34.74% surprise. The estimated earnings for the next quarter are −0.68 SEK per share. See more details about ONCOPEPTIDES AB NPV earnings.
ONCOPEPTIDES AB NPV revenue for the last quarter amounts to 26.00 M SEK despite the estimated figure of 25.28 M SEK. In the next quarter revenue is expected to reach 27.39 M SEK.
Yes, you can track ONCOPEPTIDES AB NPV financials in yearly and quarterly reports right on TradingView.
0RN4 stock has fallen by 26.29% compared to the previous week, the month change is a 37.57% fall, over the last year ONCOPEPTIDES AB NPV has showed a 62.09% decrease.
0RN4 net income for the last quarter is −81.21 M SEK, while the quarter before that showed −40.54 M SEK of net income which accounts for −100.31% change. Track more ONCOPEPTIDES AB NPV financial stats to get the full picture.
Today ONCOPEPTIDES AB NPV has the market capitalization of 611.29 M, it has decreased by 25.08% over the last week.
No, 0RN4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0RN4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOPEPTIDES AB NPV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 57.00 employees. See our rating of the largest employees — is ONCOPEPTIDES AB NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOPEPTIDES AB NPV technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOPEPTIDES AB NPV stock shows the sell signal. See more of ONCOPEPTIDES AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ONCOPEPTIDES AB NPV future price: according to them, 0RN4 price has a max estimate of 9.98 SEK and a min estimate of 3.92 SEK. Read a more detailed ONCOPEPTIDES AB NPV forecast: see what analysts think of ONCOPEPTIDES AB NPV and suggest that you do with its stocks.